Considerations for prioritising clinical research using bacteriophage
2024

Prioritizing Clinical Research on Bacteriophage Therapy

publication Evidence: moderate

Author Information

Author(s): Santini Joanne M, Edwards Sarah J.L., Tao Yiran, Elias Rodas, Schooley Robert

Primary Institution: University College London

Hypothesis

How should research priorities be set for bacteriophage therapy in the context of antimicrobial resistance?

Conclusion

Bacteriophage therapy presents a promising alternative to antibiotics, but a coordinated effort is needed to overcome regulatory and research barriers.

Supporting Evidence

  • AMR is responsible for approximately 1.2 million deaths annually.
  • Bacteriophages could be a solution for drug-resistant pathogens.
  • The traditional DALY metric has not been effectively applied to AMR globally.
  • Unique features of bacteriophages complicate standard research methodologies.
  • A coordinated effort among researchers, clinicians, and regulators is essential.

Takeaway

Bacteriophages are viruses that can kill bacteria and might help treat infections that antibiotics can't. We need to figure out how to study them better to help people.

Potential Biases

Potential biases in prioritization methods may overlook the needs of low-income countries.

Limitations

Current research lacks standardized reporting and there is no consensus on the best methods for prioritizing bacteriophage research.

Digital Object Identifier (DOI)

10.1042/EBC20240013

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication